Navigation Links
Progress toward treating infections by silencing microbes' 'smart phones'
Date:10/20/2010

So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment. The authors describe progress toward understanding and blocking this biochemical chitchat, a development that could lead to new treatments for the growing problem of antibiotic-resistant infections.

Marvin Whiteley and Holly Huse point out that bacteria use chemical signals to communicate with each other. These signals can trigger infections when their numbers reach a certain threshold a process known as "quorum sensing." Scientists around the world are trying to find potential new drugs that garble or block those signals, and in doing so, fight infection. One prime target are the 4-quinolones, signaling molecules produced by Pseudomonas aeruginosa, a common disease-causing microbe.

Their review of more than 60 years of research on 4-quinolones found promising indications that such a conversation-stopper will be developed. Scientists, for instance, now have evidence that a certain enzyme that modifies 4-quinolones can reduce infection. "These results are encouraging for the development of new therapeutics that target 4-quinolone signaling," the article noted.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Progress toward first commercial repellent for East Coasts stinker
2. Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
3. Gene-environmental interactions and MS progression is focus of new study
4. Stem cell research: What progress has been made, what is its potential?
5. 23rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress
6. At opening of XVIII International AIDS Conference, scientific, community and political leaders applaud recent progress toward universal access and urge continued momentum to finish what weve started
7. Progress made in addressing food marketing to children, but challenges remain
8. Families with rare forms of diabetes gather to celebrate progress
9. The forests of the Basque Country are progressing -- slowly, according to research group
10. 5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded
11. Study identifies key cause of chronic leukemia progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of ... Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old male ... conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is honored that ... for Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role ...
Breaking Biology Technology: